Floatz logo

Rivoceranib

Lung Diseases

Sichuan Cancer Hospital and Research InstituteSmall moleculePhase 2Dormant
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
81/ 100

Competitive context

25 Active assets in the Lung Diseases cohort.

Asset / SponsorPhaseRating
Carboplatin
Jiangmen Central Hospital
Phase 3BB
Ivacaftor
University of British Columbia
Phase 3BB
Lumacaftor
Vertex Pharmaceuticals Incorporated
Phase 3BB
Theophylline
NCIC Clinical Trials Group
Phase 3BB
Pembrolizumab
Sarah Goldberg
Phase 3B

View all 50 →

Same molecule, other indications

Rivoceranib is also rated in:

gastric cancerDormant
BBB
Indicative ·
73 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BBB
Indicative ·
72 / 100
View asset →
ApatinibDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →